Abbreviated New Drug Applications: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence); Draft Guidance for Industry; Availability, 51421-51424 [2017-24099]

Download as PDF Federal Register / Vol. 82, No. 213 / Monday, November 6, 2017 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2017–N–1064] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; State Petitions for Exemption From Preemption AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by December 6, 2017. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written SUMMARY: comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202– 395–7285, or emailed to oira_ submission@omb.eop.gov. All comments should be identified with the OMB control number 0910–0277. Also include the FDA docket number found in brackets in the heading of this document. Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–7726, PRAStaff@ fda.hhs.gov. FOR FURTHER INFORMATION CONTACT: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. SUPPLEMENTARY INFORMATION: 51421 State Petitions for Exemption From Preemption OMB Control Number 0910–0277— Extension Under section 403A(b) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 343–1(b)), States may petition FDA for exemption from Federal preemption of State food labeling and standard-of-identity requirements. Section 100.1(d) (21 CFR 100.1(d)) sets forth the information a State is required to submit in such a petition. The information required under § 100.1(d) enables FDA to determine whether the State food labeling or standard-of-identity requirement satisfies the criteria of section 403A(b) of the FD&C Act for granting exemption from Federal preemption. In the Federal Register of June 15, 2017 (82 FR 27491), FDA published a 60-day notice requesting public comment on the proposed collection of information. We received no comments. FDA estimates the burden of this collection of information as follows: TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 21 CFR 100.1(d) Number of respondents Number of responses per respondent Total annual responses Average burden per response Total hours Form of petition .................................................................... 1 1 1 40 40 1 There are no capital costs or operating and maintenance costs associated with this collection of information. The reporting burden for § 100.1(d) is minimal because petitions for exemption from preemption are seldom submitted by States. In the last 3 years, we have received one new petition for exemption from preemption; therefore, we estimate that one or fewer petitions will be submitted annually. Dated: November 1, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis. DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2017–D–3101] Abbreviated New Drug Applications: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence); Draft Guidance for Industry; Availability [FR Doc. 2017–24106 Filed 11–3–17; 8:45 am] AGENCY: BILLING CODE 4164–01–P Food and Drug Administration, HHS. ACTION: Notice of availability. The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled ‘‘ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (PreSubmission Facility Correspondence).’’ FDA is revising the draft guidance because, after issuance of the original draft guidance, the Federal Food, Drug, and Cosmetic Act (the FD&C Act) was Pmangrum on DSK3GDR082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 14:48 Nov 03, 2017 Jkt 244001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 amended by the FDA Reauthorization Act of 2017, which resulted in changes to the pre-submission of facility information. Pre-submitting facility information enables the Agency to determine whether inspection of a facility is necessary and, if so, to begin inspection planning in advance of an abbreviated new drug application (ANDA) receipt. DATES: Submit either electronic or written comments on the draft guidance by February 5, 2018 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. Submit either electronic or written comments concerning the collection of information proposed in the draft guidance by January 5, 2018. ADDRESSES: You may submit comments on any guidance at any time as follows: Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. E:\FR\FM\06NON1.SGM 06NON1 51422 Federal Register / Vol. 82, No. 213 / Monday, November 6, 2017 / Notices Pmangrum on DSK3GDR082PROD with NOTICES Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2017–D–3101 for ‘‘ANDAs: PreSubmission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence).’’ Received comments will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The VerDate Sep<11>2014 14:48 Nov 03, 2017 Jkt 244001 second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/ fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)). Submit written requests for single copies of the draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993– 0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document. FOR FURTHER INFORMATION CONTACT: Nikhil Thakur, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave. Bldg. 51, Rm. 4161, Silver Spring, MD 20993, 301–796– 5536. SUPPLEMENTARY INFORMATION: I. Background FDA is announcing the availability of a revised draft guidance for industry entitled ‘‘ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence).’’ The first draft of this document, entitled ‘‘ANDAs: PreSubmission Facility Correspondence Associated with Priority Submissions,’’ PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 was issued pursuant to 21 CFR 10.115 in June 2017. The docket number has not changed since the first draft of this document was issued, and it is not necessary to resubmit comments already submitted to the docket. The Agency will consider comments submitted with respect to the first draft of this document in finalizing the revised document. The Agency is issuing this revised draft guidance to describe the process through which prospective generic drug applicants submit facility information in advance of an original ANDA, prior approval supplement (PAS), PAS amendment, or ANDA amendment (hereafter collectively referred to as ANDA). FDA is revising the draft guidance because, after issuance of the original draft guidance, section 505(j)(11) of the FD&C Act (21 U.S.C. 355(j)(11)) as added by section 801 of the FDA Reauthorization Act of 2017 (FDARA) resulted in changes to the presubmission of facility information. In 2016 and 2017, FDA, regulated industry, and public stakeholders conducted negotiations concerning reauthorization of the Generic Drug User Fee Amendments (GDUFA II). A chief product of these congressionally mandated discussions was the ‘‘GDUFA Reauthorization Performance Goals and Program Enhancements, FYs 2018– 2022’’ (GDUFA II Commitment Letter) available at: https://www.fda.gov/ downloads/ForIndustry/UserFees/ GenericDrugUserFees/UCM282505.pdf. Together, the Generic Drug User Fee Amendments of 2017 and the GDUFA II Commitment Letter describe FDA’s performance goals, as well as changes and improvements to the user fee program. On August 18, 2017, FDARA, which reauthorized the Generic Drug User Fee Amendments (Title III) as well as other provisions related to generic drugs (Title VIII), was signed into law. In particular, section 801 of the FDARA added section 505(j)(11) to the FD&C Act to address priority review of generic drugs. One of the enhancements specified in both Title VIII, section 801 of FDARA, and the GDUFA II Commitment Letter is a mechanism to enable a shorter review goal (priority review goal) for certain priority original ANDAs, PASs, PAS amendments, and ANDA amendments through the pre-submission of facility information, including sections of the ANDA determined to be relevant by FDA. Specifically, this guidance describes: • The content and format of the facility information that should be submitted to enable FDA’s assessment of facilities listed in the pre-submission. E:\FR\FM\06NON1.SGM 06NON1 Federal Register / Vol. 82, No. 213 / Monday, November 6, 2017 / Notices Pmangrum on DSK3GDR082PROD with NOTICES • Timeframes for pre-submitting sections of the ANDA containing complete, accurate information, and the intersection of these timeframes with submission of the ANDA. • The possible outcomes of the Agency’s assessment of pre-submitted ANDA sections containing facility information. • When and how the Agency notifies an applicant about the status of the presubmitted ANDA sections containing facility information. This draft guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (PreSubmission Facility Correspondence). It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. This guidance is not subject to Executive Order 12866. II. Paperwork Reduction Act of 1995 Under the Paperwork Reduction Act of 1995 (the PRA) (44 U.S.C. 3501– 3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ‘‘Collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing the proposed collection of information set forth in this notice of availability that would result from the pre-submission of facility information. With respect to the following collection of information, FDA invites comment on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) VerDate Sep<11>2014 14:48 Nov 03, 2017 Jkt 244001 ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Title: Draft Guidance for Industry on ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (PreSubmission Facility Correspondence). Description: As described in the draft guidance, section 505(j)(11) of the FD&C Act was added by section 801 of FDARA. Pre-submitting facility information enables the Agency to determine whether inspection of a facility is necessary and, if so, to begin inspection planning in advance of ANDA receipt. This draft guidance document refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by OMB under the PRA. Existing regulations at 21 CFR 314.94 provide the content and format of an ANDA, and consistent with GDUFA II, this draft guidance describes the relevant sections of an ANDA that should be submitted as part of the presubmission of facility information. The information collections associated with the submission of these ANDA sections are approved under OMB control number 0910–0001. There are information collections proposed in the draft guidance that are not already addressed under the approved control numbers covering ANDA submissions. Section IV of the draft guidance describes the information that should be included in the presubmission of facility information to enable FDA’s facility assessment: A. The planned ANDA pre-assigned number to be submitted with the presubmission, which the applicant must request from FDA before submitting the pre-submission; B. Cover letter accompanying the presubmission, which includes a statement of justification for the expedited review request, a statement of inspection readiness, a statement identifying the Reference Listed Drug, and the anticipated date of the applicant’s ANDA submission; and C. Certification statement to be submitted with the applicant’s ANDA stating either that the applicant has made no changes to the pre-submitted facility information, or that the only change was made to exclude a facility as described in 505(j)(11)(B) of the FD&C Act. (Changes other than those permitted under 505(j)(11)(B) of the FD&C Act should be identified in the ANDA cover letter. The applicant will PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 51423 also need to confirm the accuracy of the information provided in the Form FDA 356h submitted with the ANDA, and update accordingly.) Section VI of the draft guidance describes the format used to submit the pre-submission of facility information, which is the electronic Common Technical Document (eCTD) format. Further, as explained in section V of the draft guidance, the pre-submission must be submitted not later than 60 days prior to the planned ANDA submission. We estimate that a total of approximately 220 applicants (‘‘number of respondents’’ in table 1) will submit annually approximately 275 presubmissions as described above and in the draft guidance (‘‘total annual responses’’ in table 1). We estimate that preparing and submitting the portion of each pre-submission that is not already addressed under approved control numbers covering ANDA submissions will take approximately 1.1 hours (‘‘average burden per response’’ in table 1). This includes time spent preparing and submitting a cover letter accompanying the pre-submission of facility information. We estimate that approximately 10 percent of applicants will submit statements notifying the Agency that the applicant has decided not to submit an ANDA, and we have incorporated the estimated time to prepare and submit such a statement in table 1. We estimate that approximately 198 applicants will submit annually approximately 248 certifications (‘‘total annual responses’’ in table 1) verifying either that the applicant has made no changes to the pre-submitted facility information, or that the only change was made to exclude a facility as described in 505(j)(11)(B) of the FD&C Act. We estimate that preparing and submitting each certification will take approximately 4 hours (‘‘average burden per response’’ in table 1). We base our estimates for the number of applicants and the number of presubmissions on information from our database of annual ANDA submissions, on the criteria set forth in the Agency’s Manual of Policies and Procedures 5240.3, Prioritization of the Review of Original ANDAs, Amendments, and Supplements (available at: https:// www.fda.gov/downloads/AboutFDA/ CentersOffices/OfficeofMedical ProductsandTobacco/CDER/Manualof PoliciesProcedures/UCM407849.pdf), and the number of ‘‘priority’’ submissions. Our estimate of the time applicants would need to prepare and submit the portions of each presubmission not already addressed under approved control numbers covering E:\FR\FM\06NON1.SGM 06NON1 51424 Federal Register / Vol. 82, No. 213 / Monday, November 6, 2017 / Notices ANDA submissions, as well as the presubmission certification statement (referenced in table 1), takes into consideration that much of this content is related to information already gathered for the ANDA submission. We invite comments on these estimates. TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 Number of respondents Activity Pre-Submission of Facility Information ................................ Certification statement submitted with the ANDA ............... 1 There Number of responses per respondent 220 198 Total annual responses 1.25 1.25 275 248 Average burden per response Total hours 1.1 4 303 990 are no capital costs or operating and maintenance costs associated with this collection of information. III. Electronic Access Persons with access to the internet may obtain the draft guidance at either https://www.fda.gov/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/default.htm or https://www. regulations.gov. Dated: October 31, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis. [FR Doc. 2017–24099 Filed 11–3–17; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket Nos. FDA–2010–N–0258; FDA– 2010–N–0623; FDA–2007–N–0383; FDA– 2009–N–0360; FDA–2016–N–4620; FDA– 2013–N–1496; FDA–2007–N–0220; FDA– 2017–N–1848; FDA–2017–N–1066; FDA– 2015–D–3327; FDA–2011–D–0689] Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA) is publishing a list of information collections that have been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995. SUMMARY: Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–7726, PRAStaff@ fda.hhs.gov. FOR FURTHER INFORMATION CONTACT: The following is a list of FDA information collections recently approved by OMB under section 3507 of the Paperwork Reduction Act of 1995 (44 U.S.C. 3507). The OMB control number and expiration date of OMB approval for each information collection are shown in table 1. Copies of the supporting statements for the information collections are available on the internet at https://www.reginfo.gov/public/do/ PRAMain. An Agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. SUPPLEMENTARY INFORMATION: TABLE 1—LIST OF INFORMATION COLLECTIONS APPROVED BY OMB OMB control No. Title of collection Pmangrum on DSK3GDR082PROD with NOTICES Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission to Information to a Master File in Support of Petitions; and Electronic Submission Using FDA 3053 ............................................. Voluntary Cosmetic Registration Program .............................................................................................................. Radioactive Drug Research Committees ................................................................................................................ FDA Safety Communication Readership Survey .................................................................................................... Medical Devices; Reports for Corrections and Removals ...................................................................................... Generic FDA Rapid Response Surveys .................................................................................................................. Guidance for Industry: Pharmacogenomic Data Submissions ................................................................................ Cosmetic Labeling Regulations ............................................................................................................................... Annual Reporting for Custom Device Exemption .................................................................................................... GFI: E6(R2) Good Clinical Practice; International Council for Harmonisation ....................................................... DeNovo Classification Process (Evaluation of Automatic Class II Designation) .................................................... Dated: November 1, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis. [FR Doc. 2017–24121 Filed 11–3–17; 8:45 am] BILLING CODE 4164–01–P VerDate Sep<11>2014 18:12 Nov 03, 2017 Jkt 244001 PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 E:\FR\FM\06NON1.SGM 06NON1 0910–0016 0910–0027 0910–0053 0910–0341 0910–0359 0910–0500 0910–0557 0910–0599 0910–0767 0910–0843 0910–0844 Date approval expires 9/30/2020 9/30/2020 9/30/2020 9/30/2020 9/30/2020 9/30/2020 9/30/2020 9/30/2020 9/30/2020 9/30/2020 9/30/2020

Agencies

[Federal Register Volume 82, Number 213 (Monday, November 6, 2017)]
[Notices]
[Pages 51421-51424]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-24099]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-D-3101]

Abbreviated New Drug Applications: Pre-Submission of Facility
Information Related to Prioritized Generic Drug Applications (Pre-
Submission Facility Correspondence); Draft Guidance for Industry;
Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a revised draft guidance for industry entitled
``ANDAs: Pre-Submission of Facility Information Related to Prioritized
Generic Drug Applications (Pre-Submission Facility Correspondence).''
FDA is revising the draft guidance because, after issuance of the
original draft guidance, the Federal Food, Drug, and Cosmetic Act (the
FD&C Act) was amended by the FDA Reauthorization Act of 2017, which
resulted in changes to the pre-submission of facility information. Pre-
submitting facility information enables the Agency to determine whether
inspection of a facility is necessary and, if so, to begin inspection
planning in advance of an abbreviated new drug application (ANDA)
receipt.

DATES: Submit either electronic or written comments on the draft
guidance by February 5, 2018 to ensure that the Agency considers your
comment on this draft guidance before it begins work on the final
version of the guidance. Submit either electronic or written comments
concerning the collection of information proposed in the draft guidance
by January 5, 2018.

ADDRESSES: You may submit comments on any guidance at any time as
follows:

Electronic Submissions

Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.

[[Page 51422]]

Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because
your comment will be made public, you are solely responsible for
ensuring that your comment does not include any confidential
information that you or a third party may not wish to be posted, such
as medical information, your or anyone else's Social Security number,
or confidential business information, such as a manufacturing process.
Please note that if you include your name, contact information, or
other information that identifies you in the body of your comments,
that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2017-D-3101 for ``ANDAs: Pre-Submission of Facility Information
Related to Prioritized Generic Drug Applications (Pre-Submission
Facility Correspondence).'' Received comments will be placed in the
docket and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single copies of the draft guidance to
the Division of Drug Information, Center for Drug Evaluation and
Research, Food and Drug Administration, 10001 New Hampshire Ave.,
Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. Send one
self-addressed adhesive label to assist that office in processing your
requests. See the SUPPLEMENTARY INFORMATION section for electronic
access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Nikhil Thakur, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave. Bldg. 51, Rm. 4161, Silver Spring, MD 20993, 301-796-
5536.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a revised draft guidance for
industry entitled ``ANDAs: Pre-Submission of Facility Information
Related to Prioritized Generic Drug Applications (Pre-Submission
Facility Correspondence).'' The first draft of this document, entitled
``ANDAs: Pre-Submission Facility Correspondence Associated with
Priority Submissions,'' was issued pursuant to 21 CFR 10.115 in June
2017. The docket number has not changed since the first draft of this
document was issued, and it is not necessary to resubmit comments
already submitted to the docket. The Agency will consider comments
submitted with respect to the first draft of this document in
finalizing the revised document.
The Agency is issuing this revised draft guidance to describe the
process through which prospective generic drug applicants submit
facility information in advance of an original ANDA, prior approval
supplement (PAS), PAS amendment, or ANDA amendment (hereafter
collectively referred to as ANDA). FDA is revising the draft guidance
because, after issuance of the original draft guidance, section
505(j)(11) of the FD&C Act (21 U.S.C. 355(j)(11)) as added by section
801 of the FDA Reauthorization Act of 2017 (FDARA) resulted in changes
to the pre-submission of facility information.
In 2016 and 2017, FDA, regulated industry, and public stakeholders
conducted negotiations concerning reauthorization of the Generic Drug
User Fee Amendments (GDUFA II). A chief product of these
congressionally mandated discussions was the ``GDUFA Reauthorization
Performance Goals and Program Enhancements, FYs 2018-2022'' (GDUFA II
Commitment Letter) available at: https://www.fda.gov/downloads/ForIndustry/UserFees/GenericDrugUserFees/UCM282505.pdf. Together, the
Generic Drug User Fee Amendments of 2017 and the GDUFA II Commitment
Letter describe FDA's performance goals, as well as changes and
improvements to the user fee program.
On August 18, 2017, FDARA, which reauthorized the Generic Drug User
Fee Amendments (Title III) as well as other provisions related to
generic drugs (Title VIII), was signed into law. In particular, section
801 of the FDARA added section 505(j)(11) to the FD&C Act to address
priority review of generic drugs. One of the enhancements specified in
both Title VIII, section 801 of FDARA, and the GDUFA II Commitment
Letter is a mechanism to enable a shorter review goal (priority review
goal) for certain priority original ANDAs, PASs, PAS amendments, and
ANDA amendments through the pre-submission of facility information,
including sections of the ANDA determined to be relevant by FDA.
Specifically, this guidance describes:
The content and format of the facility information that
should be submitted to enable FDA's assessment of facilities listed in
the pre-submission.

[[Page 51423]]

Timeframes for pre-submitting sections of the ANDA
containing complete, accurate information, and the intersection of
these timeframes with submission of the ANDA.
The possible outcomes of the Agency's assessment of pre-
submitted ANDA sections containing facility information.
When and how the Agency notifies an applicant about the
status of the pre-submitted ANDA sections containing facility
information.
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the current thinking of FDA on ANDAs: Pre-
Submission of Facility Information Related to Prioritized Generic Drug
Applications (Pre-Submission Facility Correspondence). It does not
establish any rights for any person and is not binding on FDA or the
public. You can use an alternative approach if it satisfies the
requirements of the applicable statutes and regulations. This guidance
is not subject to Executive Order 12866.

II. Paperwork Reduction Act of 1995

Under the Paperwork Reduction Act of 1995 (the PRA) (44 U.S.C.
3501-3520), Federal Agencies must obtain approval from the Office of
Management and Budget (OMB) for each collection of information they
conduct or sponsor. ``Collection of information'' is defined in 44
U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or
requirements that members of the public submit reports, keep records,
or provide information to a third party. Section 3506(c)(2)(A) of the
PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a
60-day notice in the Federal Register concerning each proposed
collection of information before submitting the collection to OMB for
approval. To comply with this requirement, FDA is publishing the
proposed collection of information set forth in this notice of
availability that would result from the pre-submission of facility
information.
With respect to the following collection of information, FDA
invites comment on these topics: (1) Whether the proposed collection of
information is necessary for the proper performance of FDA's functions,
including whether the information will have practical utility; (2) the
accuracy of FDA's estimate of the burden of the proposed collection of
information, including the validity of the methodology and assumptions
used; (3) ways to enhance the quality, utility, and clarity of the
information to be collected; and (4) ways to minimize the burden of the
collection of information on respondents, including through the use of
automated collection techniques, when appropriate, and other forms of
information technology.
Title: Draft Guidance for Industry on ANDAs: Pre-Submission of
Facility Information Related to Prioritized Generic Drug Applications
(Pre-Submission Facility Correspondence).
Description: As described in the draft guidance, section 505(j)(11)
of the FD&C Act was added by section 801 of FDARA. Pre-submitting
facility information enables the Agency to determine whether inspection
of a facility is necessary and, if so, to begin inspection planning in
advance of ANDA receipt.
This draft guidance document refers to previously approved
collections of information found in FDA regulations. These collections
of information are subject to review by OMB under the PRA. Existing
regulations at 21 CFR 314.94 provide the content and format of an ANDA,
and consistent with GDUFA II, this draft guidance describes the
relevant sections of an ANDA that should be submitted as part of the
pre-submission of facility information. The information collections
associated with the submission of these ANDA sections are approved
under OMB control number 0910-0001.
There are information collections proposed in the draft guidance
that are not already addressed under the approved control numbers
covering ANDA submissions. Section IV of the draft guidance describes
the information that should be included in the pre-submission of
facility information to enable FDA's facility assessment:
A. The planned ANDA pre-assigned number to be submitted with the
pre-submission, which the applicant must request from FDA before
submitting the pre-submission;
B. Cover letter accompanying the pre-submission, which includes a
statement of justification for the expedited review request, a
statement of inspection readiness, a statement identifying the
Reference Listed Drug, and the anticipated date of the applicant's ANDA
submission; and
C. Certification statement to be submitted with the applicant's
ANDA stating either that the applicant has made no changes to the pre-
submitted facility information, or that the only change was made to
exclude a facility as described in 505(j)(11)(B) of the FD&C Act.
(Changes other than those permitted under 505(j)(11)(B) of the FD&C Act
should be identified in the ANDA cover letter. The applicant will also
need to confirm the accuracy of the information provided in the Form
FDA 356h submitted with the ANDA, and update accordingly.)
Section VI of the draft guidance describes the format used to
submit the pre-submission of facility information, which is the
electronic Common Technical Document (eCTD) format. Further, as
explained in section V of the draft guidance, the pre-submission must
be submitted not later than 60 days prior to the planned ANDA
submission.
We estimate that a total of approximately 220 applicants (``number
of respondents'' in table 1) will submit annually approximately 275
pre-submissions as described above and in the draft guidance (``total
annual responses'' in table 1). We estimate that preparing and
submitting the portion of each pre-submission that is not already
addressed under approved control numbers covering ANDA submissions will
take approximately 1.1 hours (``average burden per response'' in table
1). This includes time spent preparing and submitting a cover letter
accompanying the pre-submission of facility information. We estimate
that approximately 10 percent of applicants will submit statements
notifying the Agency that the applicant has decided not to submit an
ANDA, and we have incorporated the estimated time to prepare and submit
such a statement in table 1.
We estimate that approximately 198 applicants will submit annually
approximately 248 certifications (``total annual responses'' in table
1) verifying either that the applicant has made no changes to the pre-
submitted facility information, or that the only change was made to
exclude a facility as described in 505(j)(11)(B) of the FD&C Act. We
estimate that preparing and submitting each certification will take
approximately 4 hours (``average burden per response'' in table 1).
We base our estimates for the number of applicants and the number
of pre-submissions on information from our database of annual ANDA
submissions, on the criteria set forth in the Agency's Manual of
Policies and Procedures 5240.3, Prioritization of the Review of
Original ANDAs, Amendments, and Supplements (available at: https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/UCM407849.pdf), and the number of ``priority'' submissions. Our
estimate of the time applicants would need to prepare and submit the
portions of each pre-submission not already addressed under approved
control numbers covering

[[Page 51424]]

ANDA submissions, as well as the pre-submission certification statement
(referenced in table 1), takes into consideration that much of this
content is related to information already gathered for the ANDA
submission. We invite comments on these estimates.

Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
Activity Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
Pre-Submission of Facility 220 1.25 275 1.1 303
Information....................
Certification statement 198 1.25 248 4 990
submitted with the ANDA........
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.

III. Electronic Access

Persons with access to the internet may obtain the draft guidance
at either https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or
https://www.regulations.gov.

Dated: October 31, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-24099 Filed 11-3-17; 8:45 am]
BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.